[The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations].
To retrospectively analyze the efficacy of interferon plus imatinib (IM) in patients with chronic-phase chronic myelogenous leukemia(CML-CP)and ABL kinase domain mutations. The mutation rates of ABL kinase region in patients with Sokal score low, medium and high risk CML-CP were statistically significant (6.25%, 9.42% and 47.06%,P<0.05). The response rates of interferon plus IM versus second-generation TKI in CML-CP with non-T315I ABL kinase domain mutations were comparable (61.11% vs 65.52%,P>0.05). When CML-CP patients with ABL kinase domain mutations were resistant to TKI or not accessible to second-generation TKI, interferon plus IM can be an alternative choice.
Department of Hematology, Henan Tumor Hospital, Affiliated Tumor Hospital of Zhengzhou University, Henan Institute of Hematology, Zhengzhou 450008, China.
Y L
YL
Zu
Y L
YL
Zhang
J
J
Zhou
H F
HF
Zhao
R R
RR
Gui
Z
Z
Li
S K
SK
Gao
Y P
YP
Song
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage*; D007372:Interferons / Q000008:administration & dosage* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation / Q000187:drug effects*; D010879:Piperazines; D011743:Pyrimidines; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D007372:Interferons; D016044:Fusion Proteins, bcr-abl